Mycophenolate Mofetil

Evidence Level: L2

Predicted Indications: 10

Mycophenolate Mofetil
Mycophenolate Mofetil: From Immunosuppressive Therapy to HIV Infectious Disease

## Pharmacist Assessment Report

Mycophenolate Mofetil: From Immunosuppressive Therapy to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is an immunosuppressive agent whose formal Taiwan/EU regulatory indication text is not available in this evidence pack. The TxGNN model predicts it may be effective for HIV Infectious Disease, with 10 clinical trials and 10+ publications (from a pool of 14) currently supporting this direction, though outcomes are mixed.

Quick Overview

Item	Content
Original Indication	Not documented in this evidence pack (regulatory license data unavailable). Supporting literature consistently describes MMF as an immunosuppressive agent used to prevent allograft rejection after renal, cardiac, or liver transplant.
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
EU Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (Data Gap DG002, High severity). Based on the supporting literature, mycophenolate mofetil is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that blocks de novo purine (guanosine) synthesis, thereby suppressing proliferation of activated T and B lymphocytes. This is the pharmacological basis for its established use as an immunosuppressive agent in solid organ transplantation.

The proposed link to HIV is mechanistic rather than direct antiviral: activated CD4+ T cells are the primary replication targets and reservoir for HIV, so limiting their proliferation could theoretically reduce viral replication capacity. Several pharmacokinetic studies (PMID 15355127, 12352149) further show that MMF depletes intracellular deoxyguanosine triphosphate (dGTP), a mechanism proposed to potentiate the antiviral activity of certain NRTIs such as abacavir and didanosine — an effect distinct from MMF’s classic immunosuppressive role.

However, this mechanistic plausibility has not translated into confirmed efficacy. The dedicated MAN2 study (NCT00120419) and its cardiovascular substudy (NCT00247494) remain in “Unknown” status with no reported outcomes, and the only trial designed specifically to test MMF as an antiretroviral adjunct (NCT00021489) was withdrawn with zero enrollment. Despite two decades of small pilot and cohort studies, no confirmatory large-scale trial has established clinical benefit.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01453192	Phase 3	Completed	27	Evaluated acute renal graft rejection incidence at 6 months post-transplant in HIV-infected patients on a raltegravir-containing regimen; standard immunosuppression included MMF.
NCT00038272	Phase 1/2	Completed	56	Compared DAPD alone vs. DAPD + MMF added to antiretroviral regimens in treatment-experienced HIV patients.
NCT01288131	Phase 3	Terminated	8	Compared cyclosporine + MMF vs. cyclophosphamide + prednisolone for anti-r-HuEpo associated PRCA; not an HIV-specific trial.
NCT00112593	N/A	Completed	5	Allogeneic HSCT with post-transplant cyclosporine + MMF to induce mixed hematopoietic chimerism in HIV-1 infected patients.
NCT00021489	Phase 1/2	Withdrawn	0	Designed to test MMF added to abacavir in heavily ART-experienced patients with treatment failure; withdrawn before any enrollment.
NCT06869265	Phase 2	Recruiting	56	Thiotepa/busulfan/fludarabine conditioning for haplo-HSCT in elderly high-risk AML; not HIV-related, MMF not the primary intervention.
NCT00247494	Phase 4	Unknown	90	Substudy of the MAN2 trial evaluating MMF’s effect on cardiovascular disease surrogate markers in HIV-1 infected patients.
NCT00120419	Phase 4	Unknown	90	MAN2 study: MMF vs. control in ART-naive chronic HIV-1 patients, assessing immune hyperactivation, CD4+ count decline, and plasma HIV-1 RNA.
NCT02793544	Phase 2	Completed	80	HLA-mismatched unrelated donor BMT with post-transplant cyclophosphamide, sirolimus, and MMF for GVHD prophylaxis in hematologic malignancies; not HIV-related.
NCT00009009	Phase 2	Completed	10	Renal transplantation safety/efficacy study in HIV-infected ESRD patients, using standard immunosuppression including MMF.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15213566	2004	Randomized pilot study	J Acquir Immune Defic Syndr	MMF added during structured HAART interruption in chronic HIV; assessed immune response and lymphatic tissue viral load during/after ART discontinuation.
15353978	2004	Clinical study	AIDS	Investigated whether MMF added to HAART affects plasma HIV-1 RNA decay rate and the latent reservoir in treatment-naive patients.
12352149	2002	Cohort/Clinical	J Acquir Immune Defic Syndr	MMF added to abacavir-containing ART depleted intracellular dGTP and was associated with decreased plasma HIV-1 RNA in 5 heavily pretreated patients.
11391161	2001	Pilot study	J Acquir Immune Defic Syndr	Open-label pilot of MMF + ABC/ddI/APV/RTV in 7 patients with multidrug-resistant HIV-1; therapy was well tolerated.
17885292	2007	Clinical study	AIDS	Evaluated safety, tolerability, and antiretroviral activity of DAPD (amdoxovir) with or without MMF in drug-resistant HIV-1 infection.
15871638	2005	PK study	Clin Pharmacokinet	Characterized PK/PD of low-dose MMF combined with abacavir, efavirenz, and nelfinavir in HIV-infected patients.
16379601	2005	Cohort	AIDS Res Hum Retroviruses	Found no detrimental immunological effects of adding MMF to HAART in treatment-naive acute/chronic HIV-1 patients.
15355127	2004	PK study	Clin Pharmacokinet	Examined MMF’s effect on antiretroviral drug pharmacokinetics and intracellular nucleoside triphosphate pools.
17017956	2006	Review	Curr Top Med Chem	Reviewed immunosuppressive drug strategies, including MMF, targeting chronic immune activation in HIV disease progression.
39515757	2025	Registry analysis	Am J Transplant	Long-term outcomes of induction immunosuppression (tacrolimus/MMF maintenance) in kidney transplant recipients with HIV, comparing r-ATG vs. IL2Ra induction.

EU Market Information

No marketing authorizations are recorded for mycophenolate mofetil in this evidence pack (market status: Not Marketed, 0 authorizations).

Safety Considerations

Please refer to the SmPC for safety information.

Note: A Blocking-severity data gap (DG001) was identified — TFDA/regulatory label warnings and contraindications could not be retrieved, which means this candidate cannot currently pass the S1 safety initial screening stage. This gap must be resolved before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity safety data gap (DG001: warnings/contraindications unavailable) prevents this candidate from entering the S1 safety screening stage, regardless of efficacy evidence.
Although mechanistic plausibility and several small PK/cohort/pilot studies (early 2000s) suggest MMF may modulate HIV-related immune activation and potentiate certain NRTIs, the two trials designed specifically to test this hypothesis (MAN2 and its substudy) remain in “Unknown” status with no reported results, and the sole targeted efficacy trial (NCT00021489) was withdrawn before enrollment.

To proceed, the following is needed:

Obtain TFDA/EU SmPC warnings, contraindications, and DDI data (resolve DG001, Blocking)
Obtain confirmed mechanism of action record from DrugBank (resolve DG002, High)
Determine actual outcomes of the MAN2 study (NCT00120419) and its cardiovascular substudy (NCT00247494), both currently “Unknown” status
Clarify current regulatory/market status, since this product is listed as “Not Marketed” with zero authorizations in the evidence pack
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.